Cardioprotective Effects of Iloprost

  • J. R. Parratt


It is difficult on the basis of the evidence of the studies presented by Schrör, Lucchesi, Müller et al., de Langen et al., and Numano at the symposium, and others already published, to escape the conclusion, that Iloprost has a beneficial cardioprotective effect under conditions of experimental myocardial ischemia. This evidence comes from a variety of species (cats, dogs, rats, pigs), from both in vitro (isolated heart) and in vivo studies in conscious and anesthetized animals, from a variety of models of myocardial ischemia (mechanical occlusion of a major coronary artery, coronary microembolization) in which either coronary occlusion is maintained or in which reperfusion of the ischemic area is allowed to occur, and from studies in which Iloprost is given early (pre-occlusion) or late in the ischemic period. This convincing evidence is based on histology, enzyme release, various metabolic indices of ischemia and from effects on both ischemia and reperfusion-induced ventricular arrhythmias.


Myocardial Blood Flow Cardioprotective Effect Ischemic Area Left Ventricular Filling Pressure Acute Myocardial Ischemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Coker SJ, Parratt JR (1983) Prostacyclin-antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK 36374 during coronary artery occlusion and reperfusion in anesthetized greyhounds. J Cardiovasc Pharmacol 5: 557–567PubMedCrossRefGoogle Scholar
  2. 2.
    de Langen CD J, van Gilst WH, Wesseling H (1985) Sustained protection by Iloprost of the porcine heart in the acute and chronic phases of myocardial infarction. J Cardiovasc Pharmacol 7 (5): 924–928PubMedCrossRefGoogle Scholar
  3. 3.
    Arnold G, Thiemermann C, Heymans L, Schrör K (1985) Morphological analysis of the Iloprost effects on reperfused ischemic myocardium. In: Schrör (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, pp 254–258Google Scholar
  4. 4.
    Smith III EF, Gallenkämper W, Beckmann R, Thomsen T, Mannesmann G, Schrör K (1984) Early and late administration of a PGI2-analogue, ZK 36374 (Iloprost): effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 18 (3): 163–173PubMedCrossRefGoogle Scholar
  5. 5.
    Parratt JR (1982) Drug-induced changes in myocardial blood flow following acute coronary artery ligation. In: Tillmanns H, Kübler W, Zebee (eds) Microcirculation of the heart. Springer, Berlin, Heidelberg, New York, pp 313–324Google Scholar
  6. 6.
    Schrör K, Darius H, Ohlendorf R, Matzky R, Klaus W (1982) Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbacyclin derivative (ZK 36375). J Cardiovasc Pharmacol 4: 554–561PubMedGoogle Scholar
  7. 7.
    Thiemermann C, Steinhagen-Thiessen E, Schrör K (1984) Inhibition of oxygen-centered free radical formation by the stable prostacyclin-mimetic Iloprost (ZK 36 374) in acute myocardial ischemia. J Cardiovsasc Pharmacol 6 (2): 365–366CrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1987

Authors and Affiliations

  • J. R. Parratt
    • 1
  1. 1.Department of Physiology and PharmacologyUniversity of StrathclydeGlasgowUK

Personalised recommendations